Copyright
©The Author(s) 2024.
World J Clin Cases. Mar 6, 2024; 12(7): 1272-1283
Published online Mar 6, 2024. doi: 10.12998/wjcc.v12.i7.1272
Published online Mar 6, 2024. doi: 10.12998/wjcc.v12.i7.1272
Ref. | Age (yr) | Gender (M/F) | ASA (I/II) | BMI (kg/m2) | No. of patients | |
Ye et al[20], 2023 | Remimazolam | 68. 67 ± 4.55 | 39/25 | 44/64 | NM | 64 |
Propofol | 68. 67 ± 4.55 | 36/29 | 48/65 | NM | 65 | |
Tan et al[21], 2021 | Remimazolam | 66.4 ± 4.8 | 19/14 | 18/15 | 22.7 ± 3.0 | 33 |
Propofol | 66.2 ± 5.0 | 21/12 | 18/15 | 23.2 ± 3.0 | 33 | |
Hu et al[22], 2022 | Remimazolam | 70.11 ± 7.37 | 69/104 | 20/144 | 22.75 ± 3.15 | 173 |
Propofol | 69.92 ± 7.57 | 72/101 | 26/140 | 22.73 ± 3.23 | 173 | |
Liu et al[23], 2023 | Remimazolam | 67.5 ± 4.9 | 51/58 | 11/96 | 23.7 ± 3.0 | 107 |
Propofol | 67.5 ± 5.7 | 51/56 | 10/99 | 24.0 ± 2.6 | 109 | |
Guo et al[24], 2022 | Remimazolam | 70.4 ± 3.9 | 25/14 | 7/32 | 23.0 ± 3.0 | 38 |
Propofol | 69.1 ± 4.0 | 22/16 | 7/31 | 23.0 ± 3.4 | 38 | |
Lu et al[25], 2022 | Remimazolam | 70.6 ± 4.7 | 78/122 | 6/192 | 22.2 ± 2.5 | 200 |
Propofol | 70.1 ± 4.5 | 83/117 | 17/181 | 22.2 ± 2.3 | 200 | |
Liu et al[26], 2021 | Remimazolam | 68.87 ± 2.58 | 54/61 | 37/78 | 25.35 ± 2.07 | 115 |
Propofol | 69.12 ± 2.75 | 58/59 | 46/71 | 24.75 ± 2.16 | 117 |
Ref. | No. of patients | Hypotension | Respiratory depression | Injection pain | Bradycardia | PONV | Dizziness | Successful sedation rate | Time to discharge | Time to total alert | |
Ye et al[20], 2023 | Remimazolam | 64 | 9 | 1 | 0 | 7 | NM | 1 | 64 | NM | 9 ± 1.51 |
Propofol | 65 | 47 | 3 | 8 | 30 | NM | 3 | 65 | NM | 7.67 ± 2.27 | |
Tan et al[21], 2021 | Remimazolam | 33 | 1 | NM | NM | NM | NM | NM | NM | NM | 3.82 ± 2.49 |
Propofol | 33 | 16 | NM | NM | NM | NM | NM | NM | NM | 4.33 ± 2.97 | |
Hu et al[22], 2022 | Remimazolam | 173 | 56 | 17 | 1 | 3 | 1 | NM | 172 | 19.92 ± 6.34 | 15.09 ± 4.06 |
Propofol | 173 | 88 | 31 | 8 | 3 | 0 | NM | 173 | 19.55 ± 7.6 | 13.75 ± 4.22 | |
Liu et al[23], 2023 | Remimazolam | 107 | 3 | NM | NM | 5 | 11 | 4 | 39 | NM | NM |
Propofol | 109 | 14 | NM | NM | 6 | 7 | 4 | 107 | NM | NM | |
Guo et al[24], 2022 | Remimazolam | 38 | 6 | 2 | 0 | NM | 10 | 11 | 35 | NM | NM |
Propofol | 38 | 17 | 9 | 5 | NM | 8 | 14 | 36 | NM | NM | |
Lu et al[25], 2022 | Remimazolam | 200 | 73 | 9 | 2 | 3 | NM | NM | 200 | NM | 9.8 ± 3.7 |
Propofol | 200 | 139 | 20 | 24 | 17 | NM | NM | 200 | NM | 9.3 ± 3.7 | |
Liu et al[26], 2021 | Remimazolam | 115 | 15 | 0 | 4 | 6 | 103 | NM | 111 | NM | NM |
Propofol | 117 | 12 | 0 | 15 | 9 | 101 | NM | 117 | NM | NM |
- Citation: Li FZ, Zhao C, Tang YX, Liu JT. Safety and efficacy comparison of remimazolam and propofol for intravenous anesthesia during gastroenteroscopic surgery of older patients: A meta-analysis. World J Clin Cases 2024; 12(7): 1272-1283
- URL: https://www.wjgnet.com/2307-8960/full/v12/i7/1272.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i7.1272